

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A consultee suggested that there should be special consideration given to 2 groups because of their higher needs for education and support. These groups were adolescents and “hard to reach” communities (BAME, low socio-economic backgrounds).

In previous appraisals for this indication the committee noted that it is possible that the assessment tools for assessing the severity of atopic dermatitis and the response to treatment may not be sensitive enough in people with some skin colours.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The experiences of all people of the condition will be taken into account by the appraisal committee. The committee will consider the impact of any recommendation on population groups experiencing health inequalities.

The committee should take into account skin colour and how this could affect the assessment of the severity of atopic dermatitis and response to treatment.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

Issue date: March 2021

No. The scope already states that different skin colour subgroups should be considered if evidence allows.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Henry Edwards

Date: 10/03/21